Currently in a Phase III, multi‐center trial (recruiting phase) to evaluate efficacy versus Docetaxel to address advanced or metastatic NSCLC following platinum‐based chemotherapy and anti‐PD‐1/PD‐L1 immunotherapyEstimated date of study completion is January 2025. The gene discussed is CD274; the disease is non-small cell lung carcinoma.